Skip to content

News Releases

News Releases

Shackelford Pharma Inc. Announces Positive Data from Retrospective Analysis

Vancouver BC, Canada (February 6, 2023) — Shackelford Pharma Inc. (“Shackelford” or the “Company”), a pharmaceutical company developing medicines for neurological diseases with significant unmet patient needs, is pleased to
Read More

Shackelford Pharma Congratulates Team & SAB Members on Publication

Shackelford Pharma congratulates O’Neill D’Cruz, a member of Shackelford’s clinical development team, and our Scientific Advisory Board Members Emilio Perucca and Jeffrey Buchhalter, co-authors of the article “EEG Parameters as
Read More

Shackelford Pharma Inc. Selected to Present at Life Science BC Invest in BC

Shackelford Pharma Inc. Selected to Present at Life Science BC Invest in BC Vancouver BC, Canada (October 16, 2022) — Shackelford Pharma Inc., a pharmaceutical company developing medicines for neurological
Read More

Shackelford Pharma Formalizes Scientific Advisory Board

Vancouver BC, Canada (October 16,2022) — Shackelford Pharma Inc. (“Shackelford” or the “Company”), a pharmaceutical company developing medicines for neurological diseases with significant unmet patient needs, is pleased to announce
Read More

Shackelford Pharma Joins LifeScience BC

SPI is a member of LifeSciences BC. LifeSciences BC is a non-profit, industry association which supports and represents the life science community of British Columbia through leadership, investment, advocacy and
Read More

Shackelford Pharma to Present at BIO Digital

Read More
Invest in Shackelford

Shackelford Pharma’s Regulation A Financing is now open. Investors are required to fill out the form below to begin the investment process.

Please check your JUNK/SPAM email folder if your invitation email from Dealmaker/Shackelford does not arrive in your inbox.

Invest Shackelford